Evidence map›Paper›PMID 32877501›Full record

GuidelineJornal brasileiro de nefrologia2020

Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.

José A Moura-Neto, Ana Maria Misael, Dirceu Reis da Silva, Ronaldo D'Avila, Maria Claudia Cruz Andreoli, Angiolina Kraychete, Kleyton Bastos, Marcelo Mazza do Nascimento

Abstract readPractice Guideline
In one paragraph

Guideline in Jornal brasileiro de nefrologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

José A Moura-NetoSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-1339-3731
Ana Maria MisaelSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-7815-7364
Dirceu Reis da SilvaSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-7587-0604
Ronaldo D'AvilaSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-5422-9650
Maria Claudia Cruz AndreoliSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-4599-5481
Angiolina KraycheteSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-5522-7518
Kleyton BastosSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-2098-9050
Marcelo Mazza do NascimentoSociedade Brasileira de Nefrologia, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-2876-2923

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chloroquine and hydroxychloroquine have shown promising preliminary results and have been discussed as therapeutic options for patients with Covid-19. Despite the lack of robust evidence demonstrating the benefits and justifying the use of one of these drugs, the final decision is the responsibility of the attending physician and should be individualized and shared, whenever possible. This position statement recommends dosage adjustment for these drugs in the context of renal impairment.

Indexed as

AntimalarialsChloroquineCOVID-19HydroxychloroquineRenal InsufficiencyBrazilCOVID-19 Drug TreatmentHumansNephrologyPandemicsPneumonia, ViralSocieties, MedicalAntimalarialsChloroquineHydroxychloroquine

Identifiers

PMID32877501
PMCPMC7479979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.